Pan-Canadian Analysis of Practice Patterns in Small Cell Carcinoma of the Cervix: Insights from a Multidisciplinary Survey

• Published in: Current oncology (Toronto) Vol. 31; no. 5; pp. 2610 - 2619
• Main Authors: Fan, Kevin Yijun, Chehade, Rania, Wang, Andrew Yuanbo, Sachdeva, Anjali, MacKay, Helen J, Taggar, Amandeep S
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-05-2024
• Subjects: Canada; Cancer; Carcinoma; Carcinoma, Small Cell - therapy; cervical; chemotherapy; Female; Humans; Metastasis; neuroendocrine; neuroendocrine carcinoma of the cervix; Practice Patterns, Physicians' - statistics & numerical data; radiation; small-cell carcinoma of the cervix; Surveys; Surveys and Questionnaires; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Vincristine; Canada; cervical; small-cell carcinoma of the cervix; neuroendocrine; neuroendocrine carcinoma of the cervix; radiation; chemotherapy
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31050196

Small-cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare cancer with poor prognosis, with limited data to guide its treatment. The objective of this study was to evaluate practice patterns in the management of SCNECC. A 23-question online survey on management of SCNECC was disseminated to Canadian gynecologic oncologists (GO), radiation oncologists (RO) and medical oncologists (MO). In total, 34 practitioners from eight provinces responded, including 17 GO, 13 RO and four MO. During staging and diagnosis, 74% of respondents used a trimodality imaging approach, and 85% tested for neuroendocrine markers. In early-stage (1A1-1B2) SCNECC, 87% of practitioners used a surgical-based approach with various adjuvant and neoadjuvant treatments. In locally advanced (1B3-IVA) SCNECC, 53% favored primary chemoradiation, with cisplatin and etoposide, with the remainder using surgical or radiation-based approaches. In metastatic and recurrent SCNECC, the most common first-line regimen was etoposide and platinum, and 63% of practitioners considered clinical trials in the first line setting or beyond. This survey highlights diverse practice patterns in the treatment of SCNECC. Interdisciplinary input is crucial to individualizing multimodality treatment, and there is a need for prospective trials and intergroup collaboration to define the optimal approach towards managing this rare cancer type.